Healthcare
CSPC Pharmaceuticals Group Ltd.(CSPCY)
Live Price
Offline$3.45
+0.29% today
Window Change
-3.58%
Window
May 28, 2026 β Jun 18, 2026
- Market Cap
- $95.81B
- Revenue Growth
- -8.8%
- EPS Growth
- -5.1%
- Dividend Yield
- 2.9%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 16 bars Β· May 28, 2026 β Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CSPC Pharmaceuticals Group Ltd. (CSPCY) is a Healthcare stock with a market cap of $95.81B and listed on OTC. The stock last traded around $3.45 and down 3.6% across the available one-year price window (May 28, 2026 β Jun 18, 2026). Baseline metrics include revenue growth of -8.8%, EPS growth of -5.1%, a dividend yield of 2.9%. What stands out right now is revenue -8.8%, EPS -5.1%, free cash flow +91.4% with operating margin 15.2% and ROIC 8.4%. The dividend matters to the case here, with a current yield around 2.9%. Valuation is more restrained than many high-expectation growth names at P/E 23.1 and price/sales 3.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CSPCY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-8.8% vs +7.6% peer median
Operating Margin
Below sector median
+15.2% vs +19.4% peer median
P/E
Below sector median
23.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 27, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -8.8% and EPS is at -5.1%, with operating margin around 15.2%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 2.9%, which matters if the thesis depends on income as much as growth.
Benchmark Edge
CSPCY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CSPCY
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CSPCY Max Drawdown
-11.57%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CSPCY and SPY.
Company Overview
CSPC Pharmaceuticals Group Ltd.
OTC
CSPC Pharmaceutical Group Ltd. is a leading pharmaceutical company engaged in the research, development, production, and distribution of medicines and health products. The company's primary function is to deliver high-quality and affordable drugs to meet various healthcare needs, catering to both domestic and international markets. CSPC Pharmaceutical has a diverse portfolio that includes innovative drugs, generic medicines, bulk drugs, and nutritional and healthcare products. Operating in key therapeutic areas such as cardiovascular, anti-tumor, anti-infective, and central nervous system, CSPC plays a critical role in improving public health and addressing global healthcare challenges. With a strong emphasis on research and development, CSPC invests heavily in innovation to develop new treatment modalities that address unmet medical needs and enhance patient care. In the financial market, CSPC Pharmaceutical Group holds significant importance as one of the major players in the pharmaceutical industry, known for its robust growth and strategic expansions. The companyβs commitment to quality and technological advancements positions it as a formidable entity in the global healthcare landscape, contributing to both regional and international market economies.
- Leadership
- Dr. Lei Cai
- Employees
- 19.7k
- Street Address
- No.896 Zhongshandong Street, Gaoxin District
- Mailing
- Shijiazhuang, 050035
- Region
- Shijiazhuang, China
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 23.1
- EV/EBITDA
- 13.9
- Price/Sales
- 3.4
- Price/Book
- 2.6
Growth
- Revenue
- -8.8%
- EPS
- -5.1%
- Free Cash Flow
- +91.4%
Profitability
- Gross Margin
- 65.6%
- Operating Margin
- 15.2%
- Net Margin
- 14.9%
- ROE
- 12.0%
- ROIC
- 8.4%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 2.19
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.